← Back to Clinical Trials
Recruiting Phase 4 NCT06040112

Effect of Atelocollagen Injection in Patients With Calcific Tendinitis

Trial Parameters

Condition Calcific Tendinitis of Shoulder
Sponsor Hyungsuk Kim
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 46
Sex ALL
Min Age 20 Years
Max Age 69 Years
Start Date 2023-12-06
Completion 2024-12
Interventions
Atelocollagen

Brief Summary

Assess the clinical outcomes using atelocollagen injection in patients with calcific tendinitis.

Eligibility Criteria

Inclusion Criteria: 1. Patients in whom calcification of 5mm or more is observed in plain radiographs. 2. In cases where concomitant medication is administered continuously during the clinical trial period, patients who have verified the exact prescribed medication taken within the last week and agreed to maintain the same amount throughout the study period. 3. Individuals who have agreed to participate in this study and have given written consent themselves. Exclusion Criteria: * Patients with a medical history of infectious arthritis, rheumatoid arthritis, tumors, or fractures. * Patients with hypersensitivity. * Patients with a history of anaphylactic reactions. * Patients with ongoing autoimmune diseases or a past medical history of such diseases, either in the patient or their family members. * Patients who are allergic to transplants. ⑥ Patients who are allergic to porcine (pig) proteins. ⑦ Patients deemed unsuitable for this trial based on the judgment of the trial administrator

Related Trials